

**In the Specification:**

Please amend the specification as shown:

Please delete the paragraphs on page 13, line 1 to page 15, line 23 and replace them with the following paragraphs:

Figure 15. Human ICAM-4 peptide inhibitions of HEL cell binding to human ICAM-4Fc. x-axis: binding of HEL cells in the presence of assay buffer, defined peptides or EDTA, y-axis: percentage of input cells bound. a-p shows binding to human ICAM-4Fc. a, assay buffer, b, assay buffer plus 2mM EDTA c svpFWVrms peptide (SEQ ID NO: 9), d, tRwATSRit peptide (SEQ ID NO: 10), e, aWssLahcl peptide (SEQ ID NO: 11), f, rqgktrgp peptide (SEQ ID NO: 13), g, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10), h, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11), i, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11), j, svpFWVrms peptide (SEQ ID NO: 9) plus rqgktrgp peptide (SEQ ID NO: 13), k, tRwATSRit peptide (SEQ ID NO: 10) plus rqgktrgp peptide (SEQ ID NO: 13), l, aWssLahcl peptide (SEQ ID NO: 11) plus rqgktrgp peptide (SEQ ID NO: 13), m, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus rqgktrgp peptide (SEQ ID NO: 13), n, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgktrgp peptide (SEQ ID NO: 13), o, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) plus rqgktrgp peptide (SEQ ID NO: 13), p, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11). Human ICAM-4Fc was coated at a concentration of 2.5µg/ml, peptides were used at 750µM final concentration for each peptide, and each data point is the mean of two independent assays

Figure 16. Human ICAM-4 peptide inhibitions of HEL cell binding to human ICAM-4Fc. x-axis: binding of HEL cells in the presence of assay buffer, defined peptides or EDTA, y-axis: input cells bound expressed as a percentage of binding to human ICAM-4Fc in the absence of peptides. a, assay buffer; b, assay buffer plus 2mM EDTA (26%); c, svpFWVrms peptide (SEQ ID NO: 9) (64%); d, tRwATSRit peptide (SEQ ID NO: 10) (58%); e, aWssLahcl peptide (SEQ ID NO: 11) (50%); f, rqgktrgp peptide (SEQ ID NO: 13) (105%); g, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) (52%); h,

svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) (43%); i, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) (41%); j, svpFWVrms peptide (SEQ ID NO: 9) plus rggktrgp peptide (SEQ ID NO: 13) (59%); k, tRwATSRit peptide (SEQ ID NO: 10) plus rggktrgp peptide (SEQ ID NO: 13) (55%); l, aWssLahcl peptide (SEQ ID NO: 11) plus rggktrgp peptide (SEQ ID NO: 13) (46%); m, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus rggktrgp peptide (**SEQ ID NO: 13**) (49%); n, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) plus rggktrgp peptide (SEQ ID NO: 13) (42%); o, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) plus rggktrgp peptide (SEQ ID NO: 13) (40%); p, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) (42%). Human ICAM-4Fc was coated at a concentration of 2.5µg/ml, peptides were used at 750µM final concentration for each peptide, and each data point is the mean of two independent assays.

Figure 17. Human ICAM-4 peptide inhibitions of HT1080 cell binding to human ICAM-4Fc. x-axis: binding of HT1080 cells in the presence of assay buffer, defined peptides or EDTA, y-axis: percentage of input cells bound. a -p shows binding to human ICAM-4Fc. a, assay buffer, b, assay buffer plus 2mM EDTA c svpFWVrms peptide (SEQ ID NO: 9), d, tRwATSRit peptide (SEQ ID NO: 10), e, aWssLahcl peptide (SEQ ID NO: 11), f, rggktrgp peptide (SEQ ID NO: 13), g, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10), h, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11), i, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11), j, svpFWVrms peptide (SEQ ID NO: 9) plus rggktrgp peptide (SEQ ID NO: 13), k, tRwATSRit peptide (SEQ ID NO: 10) plus rggktrgp peptide (SEQ ID NO: 13), l, aWssLahcl peptide (SEQ ID NO: 11) plus rggktrgp peptide (SEQ ID NO: 13), m, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus rggktrgp peptide (**SEQ ID NO: 13**), n, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) plus rggktrgp peptide (SEQ ID NO: 13), o, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) plus rggktrgp peptide (SEQ ID NO: 13), p, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11). Human ICAM-4Fc was coated at a concentration of 5µg/ml, peptides were used at 750µM final concentration for each peptide, and each data point is the mean of two independent assays.

Figure 18. Human ICAM-4 peptide inhibitions of HT1080 cell binding to human ICAM-4Fc. x-axis: binding of HT1080 cells in the presence of assay buffer, defined peptides or EDTA, y-axis: input cells bound expressed as a percentage of binding to human ICAM-4Fc in the absence of peptides. a, assay buffer; b, assay buffer plus 2mM EDTA (10%); c, svpFWVrms peptide (SEQ ID NO: 9) (41%); d, tRwATSRit peptide (SEQ ID NO: 10) (42%); e, aWssLahcl peptide (SEQ ID NO: 11) (71%); f, rggktrlrgp peptide (SEQ ID NO: 13) (96%); g, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) (46%); h, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) (52%); i, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) (50%); j, svpFWVrms peptide (SEQ ID NO: 9) plus rggktrlrgp peptide (SEQ ID NO: 13) (40%); k, tRwATSRit peptide (SEQ ID NO: 10) plus rggktrlrgp peptide (SEQ ID NO: 13) (39%); l, aWssLahcl peptide (SEQ ID NO: 11) plus rggktrlrgp peptide (SEQ ID NO: 13) (64%); m, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus rggktrlrgp peptide (**SEQ ID NO: 13**) (39%); n, svpFWVrms peptide (SEQ ID NO: 9) plus aWssLahcl peptide (SEQ ID NO: 11) plus rggktrlrgp peptide (SEQ ID NO: 13) (50%); o, tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) plus rggktrlrgp peptide (SEQ ID NO: 13) (48%); p, svpFWVrms peptide (SEQ ID NO: 9) plus tRwATSRit peptide (SEQ ID NO: 10) plus aWssLahcl peptide (SEQ ID NO: 11) (52%). Human ICAM-4Fc was coated at a concentration of 5µg/ml, peptides were used at 750µM final concentration for each peptide, and each data point is the mean of two independent assays.

Please delete the paragraph on page 26, line 1 to page 27 line 34 and replace it with the following paragraph:

**SEQ ID NOS: 40 and 1** – Combined nucleotide (**SEQ ID NO: 40**) and amino acid (**SEQ ID NO: 41**) sequence of mature human ICAM-4

```

1                                     20
  A  Q  S  P  K  G  S  P  L  A  P  S  G  T  S  V  P  F  W  V
GCGCAAAGCCCCAAGGGTAGCCCTCTCGCGCCCTCCGGGACCTCAGTGCCCTTTCTGGGTG
101                                     160

```

21 40  
 R M S P E F V A V Q P G K S V Q L N C S  
 CGCATGAGCCCGGAGTTTCGTGGCTGTGCAGCCGGGGAAGTCAGTGCAGCTCAATTGCAGC  
 161 220  
  
 41 60  
 N S C P Q P Q N S S L R T P L R Q G K T  
 AACAGCTGTCCCCAGCCGCGAGAATTCCAGCCTCCGCACCCCGCTGCGGCAAGGCAAGACG  
 221 280  
  
 61 80  
 L R G P G W V S Y Q L L D V R A W S S L  
 CTCAGAGGGCCGGGTTGGGTGTCTTACCAGCTGCTCGACGTGAGGGCCTTGGAGCTCCCTC  
 281 340  
  
 81 100  
 A H C L V T C A G K T R W A T S R I T A  
 GCGCACTGCCTCGTGACCTGCGCAGGAAAAACACGCTGGGCCACCTCCAGGATCACCGCC  
 341 400  
  
 101 120  
 Y K P P H S V I L E P P V L K G R K Y T  
 TACAAACCGCCCCACAGCGTGATTTTGGAGCCTCCGGTCTTAAAGGGCAGGAAATACACT  
 401 460  
  
 121 140  
 L R C H V T Q V F P V G Y L V V T L R H  
 TTGCGCTGCCACGTGACGCAGGTGTTCCCGGTGGGCTACTTGGTGGTGACCCTGAGGCAT  
 461 520  
  
 141 160  
 G S R V I Y S E S L E R F T G L D L A N  
 GGAAGCCGGGTCATCTATTCCGAAAGCCTGGAGCGCTTCACCGGCCTGGATCTGGCCAAC  
 521 580  
  
 161 180

V T L T Y E F A A G P R D F W Q P V I C  
 GTGACCTTGACCTACGAGTTTGCTGCTGGACCCCGCGACTTCTGGCAGCCCGTGATCTGC  
 581 640

181 200  
 H A R L N L D G L V V R N S S A P I T L  
 CACGCGCGCCTCAATCTCGACGGCCTGGTGGTCCGCAACAGCTCGGCACCCATTACACTG  
 641 700

201 220  
 M L A W S P A P T A L A S G S I A A L V  
 ATGCTCGCTTGGAGCCCCGCGCCACAGCTTTGGCCTCCGGTTCATCGCTGCCCTTGTA  
 701 760

221 240  
 G I L L T V G A A Y L C K C L A M K S Q  
 GGGATCCTCCTCACTGTGGGCGCTGCGTACCTATGCAAGTGCCTAGCTATGAAGTCCCAG  
 761 820

241  
 A  
 GCG  
 821-823

Underlined and in bold are the mutated residues which comprise the footprint (F18, W19, V20, R92, A94, T95, S96, R97, T91, R52, E151, T154, W93, L80, W77).

In bold and in italics are the "super-adhesive" residues involved in the N-glycosylation site (N160 and T162).

W66 and K118 are shown in bold alone.